Catherine T. Doherty, an officer at Quest Diagnostics Inc, has filed to sell 22,105 shares of the company's common stock. This transaction, which occurred on November 3, 2026, is significant as it reflects the trading activities of company executives and may indicate their confidence in the company's future.

Background

Quest Diagnostics Inc, incorporated in Delaware, operates in the medical laboratories sector. The company, with a Central Index Key (CIK) of 0001022079, is known for providing diagnostic testing services. Its fiscal year ends on December 31. Recent filings indicate ongoing trading activities by its executives, including Doherty.

What the Filing Says

The filing indicates that Doherty exercised stock options to acquire the shares she plans to sell, stating, "nature of acquisition transaction: Stock Option Exercise." The aggregate market value of the shares is reported to be approximately $5,584,607.20.

Impact

This transaction may affect Quest Diagnostics' stock performance and investor sentiment. As an insider, Doherty's actions could lead to increased scrutiny from investors and analysts, particularly in the medical laboratories sector.

What's Next

The filing does not say what happens next.

Transaction Details

The filing specifies that the shares were acquired through a stock option exercise on the same date as the sale, November 3, 2026. This indicates that Doherty exercised her options and immediately sold the shares, a common practice among executives to realize gains from their stock options.

Broker Information

The transaction was facilitated by Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI. This brokerage firm is responsible for executing the sale of the shares on behalf of Doherty.

Outstanding Shares

As of the filing date, there were approximately 110,019,073 shares of Quest Diagnostics' common stock outstanding. This context is important as it helps to understand the scale of Doherty's transaction relative to the total number of shares available in the market.

Regulatory Context

This filing is made under SEC Form 144, which is used to notify the SEC of the proposed sale of restricted or control securities. The form indicates that no securities have been sold by Doherty in the past three months, suggesting that this transaction is a significant move in her portfolio.

Future Considerations

The filing does not provide any insights into whether Doherty plans to sell additional shares in the future or if she will retain any remaining stock options. Additionally, it does not disclose any potential impact on her role within the company following this transaction.